Reuters logo
BRIEF-Sorrento provides update on two experimental immunotherapies for blood cancers
December 1, 2016 / 1:05 PM / a year ago

BRIEF-Sorrento provides update on two experimental immunotherapies for blood cancers

Dec 1 (Reuters) - Sorrento Therapeutics Inc:

* Sorrento’s TNK Therapeutics provides progress update for its anti-cd38 and cd123 car-t programs for treatment of hematological malignancies

* Sorrento Therapeutics Inc - IND filings are planned for h1 2017, with initiation of phase 1 clinical studies expected in h2 2017

* Sorrento Therapeutics - anti-cd38 car-t cells have showed specific activation through car resulting in production of cytokines and car-t proliferation

* Anti-Cd123 car-t program is in development for treatment of acute myeloid leukemia (AML)

* Sorrento Therapeutics - first-in-human studies for the car-t programs being developed to commence shortly after first half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below